SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ella Fitzgerald Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElla Fitzgerald
Date of birth1917-04-25
IdentifiersMRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640
Document date2026-11-01
AuthorOdessa Whitlow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk. Concerns: Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legs; Her glucose has dropped low after late shows, once just before an encore; The vision in her right eye has blurred, and she worries about reading lyrics and set lists. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with breakfast and the evening mealOral route1977-03-01activeS
Glipizide 10 mg oral tablet, one tablet by mouth twice daily before mealsOne tablet by mouth twice daily before breakfast and the evening mealOral route1982-09-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime30 units at bedtimeSubcutaneous route1984-04-01 to 1987-05-11completedS
Insulin glargine 100 units/mL pen, 24 units under the skin each morning24 units each morning, at the same clock time on tour, with written time-zone adjustmentsSubcutaneous route1987-05-11activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02 to 1987-05-11completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1987-05-11activeS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1986-06-02activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgeryOral route1987-05-11activeS
Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucoseOne spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911Nasal route1987-05-11activeS
Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mgOne tablet by mouth twice daily, with aspirin 81 mg once dailyOral route1987-05-26activeS
Semaglutide 0.25 mg under the skin once weekly for four weeks0.25 mg once weekly on the same day each week for four weeksSubcutaneous route1987-08-10 to 1987-09-07completedS
Semaglutide 0.5 mg under the skin once weekly0.5 mg once weekly on the same day each weekSubcutaneous route1987-09-07activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1987-08-10activeS

Procedures

ProcedureDatesStatusEvidence
Advance care planning conversation, about 18 minutes1987-06-15 to 1987-06-15completedS
Right-eye intravitreal anti-VEGF injection by the retina clinic (dose 1 of 3 monthly loading doses)1987-06-02 to 1987-06-02completedS
Podiatry: reduction of calluses under the second metatarsal heads, nail care, and fitting for protective and low-heeled stage shoes1987-06-09 to 1987-06-09completedS
Right-eye intravitreal anti-VEGF injection (dose 2 of 3)1987-06-30 to 1987-06-30completedS
Right-eye intravitreal anti-VEGF injection (dose 3 of 3)1987-07-28 to 1987-07-28completedS
Right-eye intravitreal anti-VEGF injection (first extended interval, six weeks)1987-09-08 to 1987-09-08completedS
Podiatry: reduction of calluses and nail care, three-month review1987-09-14 to 1987-09-14completedS
Right-eye intravitreal anti-VEGF injection (interval extended to eight weeks after this dose)1987-10-20 to 1987-10-20completedS

Immunizations

DateVaccineStatusEvidence
1987-06-15Pneumococcal conjugate vaccine (PCV20)completedS
1987-10-26Influenza vaccine, high-dose, 1987-1988 seasoncompletedS
1987-10-26Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1970sDiabetes affecting her eyes, with health problems beginning in the 1970sD (CLM-0007)
1970sCataract surgery, after which she returned to touring more than 40 weeks a yearD (CLM-0008)
1986Intensive care admission for heart trouble and quintuple-bypass heart surgeryD (CLM-0009)

Family History

RelativeConditionAge at deathEvidence
motherDied suddenly of a heart attack in 1932; age at death not recorded in the cited sourceD (CLM-0002)

Health Concerns

ConcernStatusEvidence
Her calves cramp when she walks through airports and to the stage, and she is afraid of what that means for her legsactiveS
Her glucose has dropped low after late shows, once just before an encoreactiveS
The vision in her right eye has blurred, and she worries about reading lyrics and set listsactiveS

Assessment

Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 7.1 on 1987-10-26; Sodium [Moles/volume] in Serum or Plasma 139 on 1987-10-26; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1987-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.94 on 1987-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M 65 on 1987-10-26; Glucose [Mass/volume] in Serum or Plasma 168 on 1987-05-11; Albumin/Creatinine [Mass Ratio] in Urine 18 on 1987-05-11; Cholesterol [Mass/volume] in Serum or Plasma 114 on 1987-10-26; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 48 on 1987-10-26; Cholesterol in HDL [Mass/volume] in Serum or Plasma 47 on 1987-10-26; Triglyceride [Mass/volume] in Serum or Plasma 96 on 1987-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1987-05-11; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1987-05-11; Hemoglobin [Mass/volume] in Blood 12.4 on 1987-05-11; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 386 on 1987-05-11; Ankle-brachial index 0.74 on 1987-05-11; Toe brachial index - right 0.46 on 1987-05-11; Toe brachial index - left 0.55 on 1987-05-11; Visual acuity best corrected Right eye by ETDRS eye chart 75 on 1987-10-26; Visual acuity best corrected Left eye by ETDRS eye chart 81 on 1987-10-26; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1987-06-15; Total score [Mini-Cog] 5 on 1987-06-15; Total score [AUDIT-C] 1 on 1987-06-15 [S]

Strengths and supports: Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complicationsactiveconfirmed E11.51S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.
Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problemsactiveconfirmed E11.3311S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.
Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgeryactiveconfirmed I25.10S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1987-05-11Hemoglobin A1c/Hemoglobin.total in Blood8.6%Below 5.7% is normal; her individualized goal is below 7.5%HighS
1987-05-11Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1987-05-11Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1987-05-11Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.59-1.04 mg/dLNormalS
1987-05-11Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1987-05-11Glucose [Mass/volume] in Serum or Plasma168mg/dL70-99 mg/dLHighS
1987-05-11Albumin/Creatinine [Mass Ratio] in Urine18mg/g<=30 mg/gNormalS
1987-05-11Cholesterol [Mass/volume] in Serum or Plasma164mg/dL<=199 mg/dLNormalS
1987-05-11Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation92mg/dLHer goal with coronary and peripheral artery disease is below 55 mg/dLNormalS
1987-05-11Cholesterol in HDL [Mass/volume] in Serum or Plasma44mg/dL>=50 mg/dLLowS
1987-05-11Triglyceride [Mass/volume] in Serum or Plasma140mg/dL<=149 mg/dLNormalS
1987-05-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
1987-05-11Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
1987-05-11Hemoglobin [Mass/volume] in Blood12.4g/dL11.6-15 g/dLNormalS
1987-05-11Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma386pg/mL232-1245 pg/mLNormalS
1987-05-11Ankle-brachial index0.62{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS
1987-05-11Ankle-brachial index0.74{ratio}1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormalLowS
1987-05-11Toe brachial index - right0.46{ratio}Above 0.70 normalLowS
1987-05-11Toe brachial index - left0.55{ratio}Above 0.70 normalLowS
1987-05-11Visual acuity best corrected Right eye by ETDRS eye chart64{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50LowS
1987-05-11Visual acuity best corrected Left eye by ETDRS eye chart81{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50NormalS
1987-06-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1987-06-15Total score [Mini-Cog]5{score}S
1987-06-15Total score [AUDIT-C]1{score}S
1987-08-10Hemoglobin A1c/Hemoglobin.total in Blood7.6%Below 5.7% is normal; her individualized goal is below 7.5%HighS
1987-08-10Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1987-08-10Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1987-08-10Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.59-1.04 mg/dLNormalS
1987-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M64mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1987-08-10Cholesterol [Mass/volume] in Serum or Plasma128mg/dL<=199 mg/dLNormalS
1987-08-10Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation64mg/dLHer goal with coronary and peripheral artery disease is below 55 mg/dLNormalS
1987-08-10Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=50 mg/dLLowS
1987-08-10Triglyceride [Mass/volume] in Serum or Plasma112mg/dL<=149 mg/dLNormalS
1987-08-10Visual acuity best corrected Right eye by ETDRS eye chart71{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50LowS
1987-08-10Visual acuity best corrected Left eye by ETDRS eye chart81{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50NormalS
1987-10-26Hemoglobin A1c/Hemoglobin.total in Blood7.1%Below 5.7% is normal; her individualized goal is below 7.5%HighS
1987-10-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1987-10-26Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1987-10-26Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
1987-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M65mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1987-10-26Cholesterol [Mass/volume] in Serum or Plasma114mg/dL<=199 mg/dLNormalS
1987-10-26Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation48mg/dLHer goal with coronary and peripheral artery disease is below 55 mg/dLNormalS
1987-10-26Cholesterol in HDL [Mass/volume] in Serum or Plasma47mg/dL>=50 mg/dLLowS
1987-10-26Triglyceride [Mass/volume] in Serum or Plasma96mg/dL<=149 mg/dLNormalS
1987-10-26Visual acuity best corrected Right eye by ETDRS eye chart75{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50LowS
1987-10-26Visual acuity best corrected Left eye by ETDRS eye chart81{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50NormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1987-05-11Body height165cmS
1987-05-11Body weight84kgS
1987-05-11Body mass index (BMI) [Ratio]30.9kg/m2S
1987-05-11Systolic blood pressure126mm[Hg]S
1987-05-11Diastolic blood pressure70mm[Hg]S
1987-05-11Heart rate62/minS
1987-05-11Respiratory rate16/minS
1987-05-11Body temperature36.6CelS
1987-05-11Oxygen saturation in Arterial blood by Pulse oximetry97%S
1987-05-26Body height165cmS
1987-05-26Body weight83.8kgS
1987-05-26Body mass index (BMI) [Ratio]30.8kg/m2S
1987-05-26Systolic blood pressure124mm[Hg]S
1987-05-26Diastolic blood pressure70mm[Hg]S
1987-05-26Heart rate60/minS
1987-05-26Respiratory rate16/minS
1987-05-26Body temperature36.5CelS
1987-05-26Oxygen saturation in Arterial blood by Pulse oximetry97%S
1987-08-10Body height165cmS
1987-08-10Body weight82.1kgS
1987-08-10Body mass index (BMI) [Ratio]30.2kg/m2S
1987-08-10Systolic blood pressure122mm[Hg]S
1987-08-10Diastolic blood pressure68mm[Hg]S
1987-08-10Heart rate62/minS
1987-08-10Respiratory rate16/minS
1987-08-10Body temperature36.6CelS
1987-08-10Oxygen saturation in Arterial blood by Pulse oximetry97%S
1987-10-26Body height165cmS
1987-10-26Body weight80.6kgS
1987-10-26Body mass index (BMI) [Ratio]29.6kg/m2S
1987-10-26Systolic blood pressure120mm[Hg]S
1987-10-26Diastolic blood pressure68mm[Hg]S
1987-10-26Heart rate60/minS
1987-10-26Respiratory rate16/minS
1987-10-26Body temperature36.6CelS
1987-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S
1987-06-15Body height165cmS
1987-06-15Body weight83.4kgS
1987-06-15Body mass index (BMI) [Ratio]30.6kg/m2S
1987-06-15Systolic blood pressure124mm[Hg]S
1987-06-15Diastolic blood pressure68mm[Hg]S
1987-06-15Heart rate60/minS
1987-06-15Respiratory rate16/minS
1987-06-15Body temperature36.6CelS
1987-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1987-05-11New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular riskfinishedS
1987-05-26Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultationfinishedS
1987-08-10Three-month review: A1c, lipids, walking program, eye treatment, and foot carefinishedS
1987-10-26Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-upfinishedS
1987-06-15Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color changecompletedGL-IWGDF-2023, GL-ADA-2026, GL-CMID-2026S
Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissuecompletedGL-ACC-PAD-2024, GL-IWGDF-PAD-2023S
Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explainedcompletedGL-ADA-2026, GL-CMID-2026S
Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%)completedGL-ADA-2026, GL-CMID-2026S
Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHgcompletedGL-ADA-2026, GL-ACC-PAD-2024, GL-AHA-CCD-2023, GL-CMID-2026S
Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materialscompletedGL-ADA-2026, GL-CMID-2026S
Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformincompletedGL-ADA-2026, GL-CMID-2026S
Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touringcompletedGL-ADA-2026, GL-ACC-PAD-2024S
Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for lifecompletedGL-ACC-PAD-2024S
Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillerscompletedGL-ACC-PAD-2024, GL-ADA-2026S
Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six monthscompletedGL-ACC-PAD-2024, GL-IWGDF-PAD-2023S
Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dLcompletedGL-ADA-2026, GL-STRIDE-2025, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months1987-10-26completedNo level 2 or 3 lows since intake; time below 70 mg/dL under 1%S
A1c below 7.5% by six months1987-10-26completedA1c 7.1%S
LDL cholesterol below 55 mg/dL by six months1987-10-26completedLDL 48 mg/dL on atorvastatin 80 mg and ezetimibeS
Walk at least four blocks without stopping by six months1987-10-26completedWalks about five blocks before calf painS
No foot ulcer, and protective footwear on and off stage, through six months1987-10-26completedNo ulcer; low-heeled custom stage shoes and protective daily shoesS

Functional Status

Mental Status